These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 19375786

  • 1. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.
    Kravchick S, Cytron S, Mamonov A, Peled R, Linov L.
    Urology; 2009 Jun; 73(6):1274-8. PubMed ID: 19375786
    [Abstract] [Full Text] [Related]

  • 2. Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate.
    Tuncel A, Ener K, Han O, Nalcacioglu V, Aydin O, Seckin S, Atan A.
    Scand J Urol Nephrol; 2009 Jun; 43(5):377-82. PubMed ID: 19921983
    [Abstract] [Full Text] [Related]

  • 3. The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).
    Bepple JL, Barone BB, Eure G.
    Urology; 2009 Nov; 74(5):1101-4. PubMed ID: 19800668
    [Abstract] [Full Text] [Related]

  • 4. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.
    Hahn RG, Fagerström T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A, Morrill B.
    BJU Int; 2007 Mar; 99(3):587-94. PubMed ID: 17407516
    [Abstract] [Full Text] [Related]

  • 5. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F, CombAT Study Group.
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M, Ramsdell J, Young J, McNicholas T.
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [Abstract] [Full Text] [Related]

  • 9. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 10. [The experience in dutasteride use before transurethral prostatic resection for large adenoma].
    Martov AG, Ergakov DV.
    Urologiia; 2008 Oct; (4):46, 48-50, 52. PubMed ID: 19054996
    [Abstract] [Full Text] [Related]

  • 11. [Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate].
    Boccon-Gibod L, Valton M, Ibrahim H, Boccon-Gibod L, Comenducci A.
    Prog Urol; 2005 Dec; 15(6):1085-9. PubMed ID: 16429657
    [Abstract] [Full Text] [Related]

  • 12. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG.
    Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
    [Abstract] [Full Text] [Related]

  • 13. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 14. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS, Roehrborn CG, Wolford E, Wilson TH.
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [Abstract] [Full Text] [Related]

  • 15. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 16. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA.
    Prostate; 2009 Nov 01; 69(15):1624-34. PubMed ID: 19588525
    [Abstract] [Full Text] [Related]

  • 17. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
    Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N.
    BJU Int; 2005 Sep 01; 96(4):572-7. PubMed ID: 16104912
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB, CombAT study group.
    Contemp Clin Trials; 2007 Nov 01; 28(6):770-9. PubMed ID: 17761460
    [Abstract] [Full Text] [Related]

  • 19. [Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study].
    Tsukamoto T, Endo Y, Narita M.
    Hinyokika Kiyo; 2009 Apr 01; 55(4):209-14. PubMed ID: 19462826
    [Abstract] [Full Text] [Related]

  • 20. Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.
    Schulman C, Pommerville P, Höfner K, Wachs B.
    BJU Int; 2006 Jan 01; 97(1):73-9; discussion 79-80. PubMed ID: 16336332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.